Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arild Holth

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Gynecologic Oncology|July 21, 2023
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinomaMargarida Varela Dos Santos, Arild Holth, Kristina Lindemann, et al.
American Journal of Clinical Pathology|May 19, 2007
The diagnostic role of claudins in serous effusionsLilach Kleinberg, Arild Holth, Eduard Fridman, et al.
Gynecologic Oncology|October 27, 2012
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastasesBen Davidson, Arild Holth, Mai T P Nguyen, et al.
Gynecologic Oncology|August 6, 2014
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusionsAna Slipicevic, Arild Holth, Ellen Hellesylt, et al.
Virchows Archiv : an International Journal of Pathology|June 24, 2017
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcomaBen Davidson, Ellen Hellesylt, Arild Holth, et al.
Molecular Cancer|April 19, 2015
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinomaDag Andre Nymoen, Arild Holth, Thea E Hetland Falkenthal, et al.
Human Pathology|December 8, 2015
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survivalBen Davidson, Arild Holth, Ellen Hellesylt, et al.
Gynecologic Oncology|May 29, 2018
Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinomaBen Davidson, Marianne Bjørnerem, Arild Holth, et al.
Virchows Archiv : an International Journal of Pathology|April 6, 2012
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastasesThea Eline Hetland, Arild Holth, Janne Kærn, et al.
Virchows Archiv : an International Journal of Pathology|February 8, 2026
The specificity of HEG1 as mesothelioma marker depends on the differential diagnosisBen Davidson, Lara Maria Stričak, Arild Holth, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Gynecologic Oncology|July 21, 2023
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinomaMargarida Varela Dos Santos, Arild Holth, Kristina Lindemann, et al.
American Journal of Clinical Pathology|May 19, 2007
The diagnostic role of claudins in serous effusionsLilach Kleinberg, Arild Holth, Eduard Fridman, et al.
Gynecologic Oncology|October 27, 2012
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastasesBen Davidson, Arild Holth, Mai T P Nguyen, et al.
Gynecologic Oncology|August 6, 2014
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusionsAna Slipicevic, Arild Holth, Ellen Hellesylt, et al.
Virchows Archiv : an International Journal of Pathology|June 24, 2017
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcomaBen Davidson, Ellen Hellesylt, Arild Holth, et al.
Molecular Cancer|April 19, 2015
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinomaDag Andre Nymoen, Arild Holth, Thea E Hetland Falkenthal, et al.
Human Pathology|December 8, 2015
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survivalBen Davidson, Arild Holth, Ellen Hellesylt, et al.
Gynecologic Oncology|May 29, 2018
Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinomaBen Davidson, Marianne Bjørnerem, Arild Holth, et al.
Virchows Archiv : an International Journal of Pathology|April 6, 2012
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastasesThea Eline Hetland, Arild Holth, Janne Kærn, et al.
Virchows Archiv : an International Journal of Pathology|February 8, 2026
The specificity of HEG1 as mesothelioma marker depends on the differential diagnosisBen Davidson, Lara Maria Stričak, Arild Holth, et al.
Pageof 6